财务业绩 - 公司第二季度总收入为2260万美元，同比增长35%[7] - 生物制药业务收入增长117%至1320万美元[7] - 企业客户收入增长8%至800万美元[8] - 退伍军人事务部百万退伍军人计划的人群测序收入下降57%至130万美元[8] - 公司第二季度净亏损1280万美元，同比下降47%[8] 其他收益 - 公司获得3000万美元的其他收益，主要为与Tempus公司签订的认股权证的公允价值变动收益[8] 财务状况 - 公司现金、现金等价物和短期投资总额为8700万美元[8] - 公司现金及现金等价物为47,747,000美元[19] - 公司短期投资为39,225,000美元[19] - 公司应收账款净额为12,921,000美元[19] - 公司存货及其他递延成本为9,164,000美元[19] - 公司预付费用及其他流动资产为4,046,000美元[19] - 公司物业、厂房及设备净额为52,662,000美元[19] - 公司经营租赁使用权资产为17,166,000美元[19] - 公司总资产为185,502,000美元[19] - 公司应付账款为9,936,000美元[19] - 公司应计及其他流动负债为19,248,000美元[19] 未来展望 - 公司预计2024年全年总收入将在7900万至8100万美元之间，高于之前的指引[10] - 公司预计2024年全年非GAAP净亏损约7500万美元，低于之前的指引[10] - 公司预计2024年全年现金使用约6000万美元，低于之前的指引[10]

SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) today announced that they have entered into an agreement to cross-license patent estates covering tumorinformed approaches to detect minimal residual disease (MRD). The agreement helps solidify each company's freedom to operate in the MRD market and broadens patient access to the benefits of MRD testing. "Myriad an ...

财务数据和关键指标变化 - 公司第一季度总收入为1950万美元,同比增长4% [29] - 生物医药业务收入同比增长55% [29] - 毛利率为20.1%,同比增加3个百分点 [30] - 经营费用为2440万美元,同比下降29% [31] - 净亏损为1300万美元,同比减少54% [32][33] - 公司现金及短期投资为9540万美元,预计现金可持续到2026年第一季度 [34] 各条业务线数据和关键指标变化 - 生物医药业务收入同比增长55%,主要来自ImmunoID NeXT和NeXT Personal MRD检测产品 [29] - 个性化癌症疫苗业务也有良好表现 [21][22] - 人口测序业务收入约为150万美元 [35] 各个市场数据和关键指标变化 - 公司未具体披露各个市场的数据和指标变化 公司战略和发展方向及行业竞争 - 公司将NeXT Personal MRD检测产品定位为公司的核心增长引擎,制定了"Win-in-MRD"战略 [10] - 战略包括:1)聚焦肺癌、乳腺癌和免疫治疗监测等领域 [10][11][12] 2)与Royal Marsden、VHIO等机构合作开展临床研究,为获得报销支付做准备 [15][16] 3)与生物制药公司合作,在临床试验中使用NeXT Personal [18] 4)与Tempus合作商业化NeXT Personal [19][20] - 公司还在持续创新,已获得4项新专利,并在知识产权保护方面采取行动 [25][26] - 公司认为FDA最新发布的LDT监管指引有利于公司 [38][39] 管理层对经营环境和未来前景的评论 - 管理层对NeXT Personal MRD检测产品的市场前景和公司未来发展前景持乐观态度 [8][9][10][18][19][20] - 认为公司有望在MRD检测领域建立行业领先地位 [10][13][18] - 预计2024年全年收入将达7600万-7800万美元,高于此前预期 [35] 问答环节重要的提问和回答 问题1 **Madison Pasterchick 提问** 询问FDA最新LDT监管指引对公司NeXT Dx和NeXT Personal的影响 [38][39] **Chris Hall 回答** 公司认为新指引整体有利于公司,公司已做好相关准备,两款产品都已获得纽约州批准 [39] 问题2 **Vidyun Bais 提问** 询问2024年收入增长的具体驱动因素 [46][47] **Aaron Tachibana 回答** ImmunoID NeXT和NeXT Personal MRD检测产品是主要增长动力,NeXT Personal增长尤其强劲 [46][47] 问题3 **Thomas Flaten 提问** 询问NeXT Dx和NeXT Personal两款产品的协同发展计划 [69][70] **Chris Hall 回答** 公司看到客户倾向同时使用两款产品,未来会继续推动两款产品协同发展

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-38943 Personalis, Inc. (Exact Name of registrant as specified in its charter) Delaware 27-5411038 (State or other jurisdic ...

Exhibit 99.1 Personalis Reports First Quarter 2024 Financial Results Raises full year revenue guidance due to greater pharma testing demand FREMONT, Calif. – May 8, 2024 – Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2024 ended March 31, 2024, and provided recent business highlights. Recent Business Highlights • The analytical validation for the company’s NeXT Personal MRD test was published in Oncotarget on ...

Personalis, Inc. (NASDAQ:PSNL) Q4 2023 Earnings Conference Call February 28, 2024 5:00 PM ET Company Participants Caroline Corner - Investor Relations Christopher Hall - President and Chief Executive Officer Aaron Tachibana - Chief Financial Officer and Chief Operating Officer Richard Chen - Executive Vice President, R&D, and Chief Medical Officer Conference Call Participants Madison Pasterchick - Morgan Stanley Vidyun Bais - BTIG Daniel Sammarco - TD Cowen Operator Greetings, and welcome to the Personalis ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______. Commission File Number 001-38943 Personalis, Inc. (Exact name of Registrant as specified in its Charter) Delaware 27-5411038 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 6600 Dumbarton Circle Fremont, California 94555 W ...

公司业绩发布 - Personalis公司将于2024年2月28日发布2023年第四季度和全年财务业绩[1] - Personalis公司将在当天下午2:00太平洋时间/下午5:00东部时间举行电话会议和网络直播，讨论其财务业绩和最新亮点[1] - 感兴趣的各方可通过拨打877-451-6152（国内）或201-389-0879（国际）来参加电话会议，也可通过访问公司网站的活动部分进行网络直播[2] 公司产品介绍 - Personalis公司致力于通过突破性的个性化测试来改变癌症的积极管理[3] - Personalis公司的产品旨在在最早的时间点检测到微小残留疾病（MRD）和复发，基于超全面的基因组分析选择靶向疗法，并增强药物开发的生物标志策略[4]

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the following investor conferences: BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference Participating on Tuesday, February 13, 2024 at The Cliff Lodge in Snowbird, UT 44th Annual Cowen Healthcare Conference Presenting on Wednesday, March 6, 2024 at 12:50 p.m. Eastern Time at the Boston Marriott Copley Place in Bost ...

FREMONT, Calif. & SAN DIEGO--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, and ClearNote Health, Inc., a pioneer in epigenomic technologies, today unveiled an alliance through which Personalis will expand its pharmaceutical service offerings by distributing ClearNote’s cutting-edge epigenomic 5-hydroxymethylcytosine (5hmC) platform. “We have built a unique pharma channel based on our industry-leading tissue and MRD assays and ClearNote Health’s blood-based ep ...